CERTIFICATE OF ANALYSIS

REPORTER VIRUS PARTICLES

DESCRIPTION	
Product	RVP-1402L, Zaire ebolavirus (EBOV) Reporter Virus Particles (RVPs)
Lot	FL-1166B
Strain	Mayinga/76
Reporter	*Renilla* luciferase
Size	1.0 mL/vial
Packaging	20% FBS/DMEM
Recommended Starting Input	1 µL per well (96-well plate) for a S:B ≥ 200*
Mycoplasma Test	Negative
Manufacture Date	July 2026
Expiration Date	July 2028

SAFETY & HANDLING	
Shipping	Shipped on dry ice
Stability and Storage	Store at ≤ -80°C upon receipt

* Determined in the HEK-293T cell line. Signal-to-background values can vary depending on instrument make, model, and/or calibration.

EBOV RVPs are used to test the ability of serum, antibodies, and drugs to neutralize EBOV infectivity. RVPs display antigenically correct glycoprotein pseudotyped on replication-incompetent virus particles that contain a heterologous VSV core. RVPs are capable of a single round of infection and carry a genome that expresses a *Renilla* luciferase reporter gene upon infection. RVPs are produced in HEK-293T cells using plasmids encoding the glycoproteins.

EBOV RVPs are derived from recombinant vesicular stomatitis virus (VSV) from which the VSV glycoprotein gene has been deleted and replaced with a reporter gene (VSVΔG). RVPs are derived from biological materials and should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment. RVPs are not to be used in humans or in animals raised for food.

Thaw tubes in a 37°C water bath for 3 minutes and place on ice until ready to use. RVPs will appear as a translucent, pink solution. Gently mix prior to use and pulse tube for 3 seconds at high speed in a tabletop microfuge to recover all volume from the tube. Vortexing of RVPs should be avoided. Re-freezing of RVPs is not recommended.

Integral Molecular | 25 N. 38th Street, Suite 800, Philadelphia, PA 19104

215.966.6061
info@integralmolecular.com
www.integralmolecular.com

INFECTIVITY AND NEUTRALIZATION DATA





Infectivity determined in HEK-293T cells (recommended product: ATCC Catalog # CRL-3216). Infectivity values represent the average of two independent vials, with each vial tested in technical quadruplicate.

Neutralization utilized 1 µL of EBOV RVPs in a 384-well plate.

Renilla luciferase activity measured using the Promega *Renilla* luciferase assay system (Promega #E2810). Sample luminescence was read using a PerkinElmer EnVision plate reader.

SIGNAL TO BACKGROUND	
RVP 384-well Input (µL)	**Signal: Background**
20	44,149
10	23,187
5	13,723
2.5	8,351
1.25	4,277
0.63	2,119
0.31	1,092

Signal to background is calculated using mock infected cells as the negative control value.

Christina Go, PhD
Senior Application Scientist, Virology
cgo@integralmolecular.com
Integral Molecular
One uCity Square
25 N. 38th Street, Suite 800
Philadelphia, PA 19104

Jennifer Kilgore
Senior Project Manager/Quality Assurance, Virology
jkilgore@integralmolecular.com
Integral Molecular
One uCity Square
25 N. 38th Street, Suite 800
Philadelphia, PA 19104